Comparison of Antimicrobial Stewardship and Infection Prevention and Control Activities and Resources Between Low-/Middle- and High-income Countries

Paola Villanueva, MBBS, BMedSci,**†‡ Susan E. Coffin, MD, MPH,§¶ Amha Mekasha, MD, MSc,**
Brendan McMullan, BMed,††‡ §§ Mark F. Cotton, MD, PhD,¶¶ and Penelope A. Bryant, PhD****†††

**  From the *Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia; ‡Infectious Diseases Group, Murdoch Children’s Research Institute, Parkville, Victoria, Australia; †Department of General Medicine, Royal Children’s Hospital Melbourne, Parkville, Victoria, Australia; §Division of Infectious Diseases, Children’s Hospital of Philadelphia, PA; ¶University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; §§Department of Paediatrics and Child Health, Tikur Anbesa Specialized Hospital, Ethiopia; ††College of Health Sciences, Addis Ababa University, Ethiopia; †††Department of Immunology and Infectious Diseases, Sydney Children’s Hospital, Randwick, Sydney, Australia; ‡‡School of Women’s and Children’s Health, University of New South Wales, Sydney, Australia; §§National Centre for Infections in Cancer, University of Melbourne, Melbourne, Australia; §§‡Tygerberg Children’s Hospital, Tygerberg, South Africa; §§¶¶Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg, South Africa; §§§Infectious Diseases and Hospital-in-the-Home Departments, The Royal Children’s Hospital Melbourne, Parkville, Victoria, Australia; and †††Clinical Paediatrics Group, Murdoch Children’s Research Institute, Parkville, Victoria, Australia.

*P A; †part, supported by the Victorian government infrastructure support program. The authors have no conflicts of interest to disclose. Address for correspondence: Penelope A. Bryant, PhD, The Royal Children’s Hospital, Flemington Rd, Parkville, Victoria 3052, Australia. E-mail: penelope.bryant@rch.org.au.

Accepted for publication June 22, 2021

From the *Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia; ‡Infectious Diseases Group, Murdoch Children’s Research Institute, Parkville, Victoria, Australia; †Department of General Medicine, Royal Children’s Hospital Melbourne, Parkville, Victoria, Australia; §Division of Infectious Diseases, Children’s Hospital of Philadelphia, PA; ¶University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; §§Department of Paediatrics and Child Health, Tikur Anbesa Specialized Hospital, Ethiopia; ††College of Health Sciences, Addis Ababa University, Ethiopia; †††Department of Immunology and Infectious Diseases, Sydney Children’s Hospital, Randwick, Sydney, Australia; ‡‡School of Women’s and Children’s Health, University of New South Wales, Sydney, Australia; §§National Centre for Infections in Cancer, University of Melbourne, Melbourne, Australia; §§‡Tygerberg Children’s Hospital, Tygerberg, South Africa; §§¶¶Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg, South Africa; §§§Infectious Diseases and Hospital-in-the-Home Departments, The Royal Children’s Hospital Melbourne, Parkville, Victoria, Australia; and †††Clinical Paediatrics Group, Murdoch Children’s Research Institute, Parkville, Victoria, Australia.

P A; †part, supported by a Medical Research Futures Fund Australia Investigator Grant and a Melbourne Campus Clinician Scientist Fellowship, Melbourne, Australia. The Clinical Paediatrics research group, MCRI is, in part, supported by the Victorian government infrastructure support program. The authors have no conflicts of interest to disclose. Address for correspondence: Penelope A. Bryant, PhD, The Royal Children’s Hospital, Flemington Rd, Parkville, Victoria 3052, Australia. E-mail: penelope.bryant@rch.org.au.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (www.pidj.com).

Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.

The Pediatric Infectious Disease Journal • Volume 41, Number 3S, March 2022

The increasing spread of antimicrobial resistance (AMR) is a global public health threat. The World Health Organization (WHO) has outlined a global action plan to address AMR,1 highlighting the key roles of antimicrobial stewardship (AMS) and infection prevention and control (IPC) measures in confronting this problem. AMS, through evidence-based interventions designed to optimize rational antimicrobial use, can decrease the rate of development and acquisition of AMR.2,3 Concurrently, the spread of AMR can also be prevented through effective IPC practices.1 AMR is higher in low- and middle-income countries (LMIC) than high-income countries (HIC),4 but to date, AMS and IPC efforts in children have largely concentrated in HIC. LMIC face unique challenges requiring special attention and context-appropriate responses. These include constraints in healthcare systems and diagnostic infrastructure,1 unregulated nonprescription availability of antibiotics leading to widespread antibiotic misuse which fuels AMR,5 limited access to quality-assured pharmaceuticals, higher patient-provider ratios and fewer resources and funding to instigate local AMR surveillance and control.6

There is paucity of information pertaining to children’s healthcare and risk of AMR across LMIC settings. The aims of this global survey were to compare AMS and IPC resources and activities between LMIC and HIC as assessed by clinicians working in those settings.

METHODS

An online questionnaire relating to AMS and IPC resources and activities was developed by members of the World Society of Pediatric Infectious Diseases AMR Declaration Working Group. It was based on a previous survey developed for AMS resources in children and adapted with the support of the African Society for Pediatric Infectious Diseases to include questions relevant to LMIC settings and IPC (Supplemental Digital Content 1; http://links.lww.com/INF/E515). It was distributed to clinicians in September 2020 via professional networks and Twitter to members of the World Society of Pediatric Infectious Diseases regional member societies: African, Asian, Australasian, European, North American and South American pediatric infectious diseases societies. Responses were entered online directly via REDCap (Research Electronic Data
Capture; Vanderbilt University, Nashville, TN,10,11 and the survey link was open until November 30, 2020. The analysis was limited to one respondent per hospital/healthcare setting. In cases of multiple respondents for the same institution, survey responses were amalgamated. Statistical comparisons were made with $\chi^2$ test for categorical variables and $t$ test for continuous variables. The classification of countries into LMIC and HIC by income was based on the 2020 World Bank classification.12

**RESULTS**

The survey was completed by 146 clinicians in 135 distinct hospitals/healthcare settings in 66 countries across 6 continents; 39 LMIC and 27 HIC (Fig. 1). Clinicians from more than 10 disciplines completed the survey, most commonly pediatric infectious diseases (ID) physicians/trainees (60/135, 44%), followed by general pediatricians/trainees (38/135, 28%). In both LMIC and HIC, participating healthcare settings were most frequently tertiary pediatric hospitals (38/89 [43%] and 29/46 [63%], respectively; Table 1). The pediatric team was a more likely to review over 50 patients per day in LMIC hospitals (42/89, 47%) than HIC hospitals (12/46, 26%; $P = 0.01$). Pediatric (including neonatal) hospital bed numbers were lower in LMIC than HIC (median 70 [interquartile range, 29–120] versus 145 [interquartile range, 51–300], respectively).

**Antimicrobial Stewardship Resources**

Formal AMS programs existed in fewer LMIC than HIC healthcare settings (37/89 [42%] versus 35/46 [76%], $P = 0.0001$; Fig. 2A). The majority of AMS programs in both LMIC and HIC formally included pediatric patients (86% and 89%, respectively). Within LMIC, these programs were predominantly available in tertiary pediatric hospitals and public hospitals in medium to large cities (26/32, 81%).

In LMIC healthcare settings, the most common personnel on AMS teams were general pediatricians (78/89, 88%), whereas in HIC settings these were pediatric ID and adult ID physicians (each 39/46, 85%; Fig. 2B). The greatest difference in personnel resources was the availability of AMS pharmacists: 15/89 (17%) in LMIC compared with 37/46 (80%) in HIC ($P < 0.001$). Within nontertiary/noncity public hospitals in LMIC, the most common AMS personnel were general pediatricians (22/26, 85%).

**Antibiotic Guidelines**

Antibiotic guidelines were less frequently used in LMIC than in HIC healthcare settings (Fig. 3A), but the difference in specific guideline use was only significant in the highly specialized setting of hematology/oncology services, with guidelines for febrile neutropenia in 27/28 (96%) of healthcare settings in HIC, compared with 33/43 (77%) ($P = 0.04$) in LMIC.

Most hospital respondents in LMIC (72/80, 90%) were aware of the WHO Integrated Management of Childhood Illness guide; however, fewer than half of their hospital antibiotic guidelines were developed in line with the guide (36/80, 45%). Overall, 55/135 (41%) were aware of the WHO Access Watch Reserve classification of antibiotic choice and 28/135 (21%) were aware of the Australian and New Zealand Pediatric Infectious Diseases IV oral guideline for antibiotic duration; proportions were similar for LMIC and HIC.

**Review of Antimicrobial Prescribing**

Over half of all facilities conducted AMS/ID rounds, although they were less likely to occur in LMIC than HIC (47/89 [53%] versus 37/46 [80%], $P = 0.002$). Moreover, AMS/ID rounds frequently occurred only in response to specific patient referrals, with unsolicited regular AMS rounds only occurring in 29/89 (33%) LMIC and 23/46 (50%) HIC facilities ($P = 0.04$).

Point-of-care interventions relating to antimicrobial prescribing—including review of choice, dose, duration, narrowing based on microbiology results, intravenous to oral switch—occurred at least sometimes in most hospitals (LMIC 71%–79% compared with HIC 84%–91%; Fig. 3B). The most common point-of-care intervention in LMIC hospitals was intravenous to oral switch (63/80, 79%) versus de-escalation based on microbiology results in HIC hospitals (39/43, 91%).

Facilities in LMIC were less likely to have a system for restricting use of broad-spectrum/expensive antimicrobials as compared with those in HIC (40/89 [45%] versus 30/46 [65%], $P = 0.03$). The most common intervention in both LMIC (25/40, 63%)

![FIGURE 1. Global map of responses describing local healthcare institutions.](https://www.pidj.com)
and HIC (23/30, 77%) settings was pre-approval of restricted antibiotics. The second most common intervention (18/40, 45%) in LMIC settings was limiting prescribing of restricted antibiotics to certain physicians (eg, named or a designated level of seniority). Whereas in HIC, regular audits of restricted drug use and accountability to hospital management were more common (12/30, 40%). These systems were reported as mostly working in LMIC settings was limiting prescribing of restricted antibiotics was less common in LMIC (26/89, 29%) versus HIC settings (22/46, 48%; P = 0.03).

**Antibiotic Availability**

Substantial differences existed in the reported availability of antibiotics between LMIC and HIC (Fig. 3C). For the sickest patients, intravenous antibiotics were only reliably available in 50/80 (62%) LMIC hospitals versus 36/43 (84%) HIC hospitals (P = 0.01). Likewise, broad-spectrum antibiotics (such as beta-lactams/beta-lactamase inhibitors) were always available in only 28/80 (35%) LMIC hospitals compared with 28/43 (65%) HIC hospitals (P = 0.001). For 12/80 (15%) LMIC facilities, antibiotics were frequently not available.

The WHO recommends that only antibiotics on the Access list13 be used for empirical treatment (amikacin, amoxicillin, amoxicillin + clavulanic acid, ampicillin, benzylpenicillin, cefalexin, cefazolin, chloramphenicol, clindamycin, claxocillin/flucloxacillin, doxycycline, gentamicin, metronidazole, nitrofurantoin, penicillin V, spectinomycin and trimethoprim/sulfamethoxazole). Empirical first-line antibiotics were limited to WHO Access antibiotics in approximately half of LMIC (48/89, 54%) and HIC (22/46, 48%) healthcare settings (P = 0.45). Reliable availability of these antibiotics was less common in LMIC (26/89, 29%) versus HIC settings (22/46, 48%; P = 0.03).

**Infection Prevention and Control Resources**

IPC resources were uniformly lower in LMIC than HIC settings. A formal IPC program/team existed in 52/89 (58%) LMIC healthcare settings and in 40/46 (89%) HIC settings (P = 0.001; Fig. 2A), although most IPC programs included pediatric patients. Infection control practitioners were the most common personnel on IPC teams in both LMIC (37/89, 42%) and HIC (33/46, 72%) facilities (Fig. 2C).

**Infection Control Interventions**

IPC interventions (eg, by infection control nurses) included promoting and auditing hand hygiene, surveillance of healthcare-associated infections and managing outbreaks. Similar proportions of LMIC and HIC facilities reported that these activities occurred at least sometimes (Fig. 4A). In all healthcare settings, promoting hand hygiene with education and posters was the most common IPC intervention: 73/89 (82%) in LMIC and 42/46 (91%) in HIC.

**Equipment and Consumable Resources**

Most LMIC hospitals reported shortages of equipment and consumables either often or always (Fig. 4B). Shortages included, sinks near patient beds, a reliable and continuous water supply for handwashing, antiseptic hand rub near patient beds, disposable gloves, full personal protective equipment (PPE), boxes for used

---

**TABLE 1. Demographics of Respondents and Healthcare Settings**

| Role of responding clinician | Overall, Pediatric hospital | Large/medium hospital | Small/rural hospital | Private hospital | Other |
|-----------------------------|-----------------------------|-----------------------|---------------------|-----------------|-------|
| Pediatric ID physician/trainee | n = 89                      | n = 38                | n = 25              | n = 3           | n = 9  |
| General pediatrician/trainee | n = 24                      | n = 27                | n = 11              | n = 3           | n = 10 |
| Microbiologist              | n = 11                      | n = 12                | n = 4               | n = 1           | n = 0  |
| General practitioner/PHP     | n = 4                       | n = 4                 | n = 1               | n = 2           | n = 4  |
| Neonatologist                | n = 3                       | n = 2                 | n = 0               | n = 1           | n = 0  |
| General adult physician/PHP  | n = 0                       | n = 0                 | n = 0               | n = 0           | n = 0  |
| General pediatric nurse      | n = 1                       | n = 0                 | n = 0               | n = 0           | n = 0  |
| General pharmacist           | n = 1                       | n = 0                 | n = 0               | n = 0           | n = 0  |
| Other*                       | n = 8                       | n = 3                 | n = 4               | n = 0           | n = 0  |

**Availability of specialty**

| General pediatrics          | n = 83                      | n = 35                | n = 24              | n = 13           | n = 8  |
| General pediatric surgery   | n = 63                      | n = 33                | n = 17              | n = 9            | n = 4  |
| Hematology/oncology         | n = 43                      | n = 27                | n = 6               | n = 7            | n = 3  |
| Bone marrow transplant       | n = 15                      | n = 12                | n = 1               | n = 0            | n = 1  |
| Solid organ transplant       | n = 11                      | n = 12                | n = 0               | n = 1            | n = 1  |
| Cardiotoracic/neurosurgery  | n = 43                      | n = 27                | n = 6               | n = 4            | n = 2  |
| ICU (pediatric * adults)    | n = 61                      | n = 39                | n = 15              | n = 10           | n = 2  |
| Neonatal ICU                | n = 55                      | n = 32                | n = 13              | n = 1            | n = 1  |
| Special care nursery        | n = 45                      | n = 21                | n = 13              | n = 1            | n = 1  |
| Obstetrics                  | n = 47                      | n = 20                | n = 14              | n = 3            | n = 4  |

**Pediatric patients reviewed per day (N)**

| < 25                        | n = 19                      | n = 21                | n = 2                | n = 5            | n = 1  |
| 25–< 50                     | n = 21                      | n = 24                | n = 9                | n = 5            | n = 1  |
| 50–< 100                    | n = 17                      | n = 19                | n = 7                | n = 3            | n = 1  |
| ≥ 100                       | n = 25                      | n = 28                | n = 12               | n = 10           | n = 3  |

*One critical care clinician, others not specified.
†Total inpatients and outpatients reviewed by respondent’s team per day.
ICU indicates intensive care unit; ID, infectious diseases; PHP, primary healthcare provider.
sharps near blood-taking and daily cleaning in patient areas. These deficits were very occasionally noted in HIC hospitals.

Reuse of equipment, including oxygen masks (39%), nasal prongs (25%), PPE (20%), endotracheal tubes (11%), nasogastric tubes (9%) and syringes (8%), was common in LMIC healthcare settings (Fig. 4C). Three LMIC healthcare settings had no protocol for cleaning equipment. In HIC, PPE was reused in 15% of healthcare settings and the remainder in up to 4% of settings. Nasogastric tubes were not reused in HIC healthcare settings.

A minimum distance between pediatric beds/neonatal cots was maintained less often in LMIC than HIC hospitals (45/80 [56%] versus 34/43 [79%], \( P = 0.01 \)). The most common minimum distance was 1 meter (range 1–3 meters) in LMIC hospitals. In HIC hospitals, single-patient rooms were most commonly reported, and the same distance range (1–3 meters) for those not in separate rooms.

Microbiology Resources

Most hospitals had access to laboratory services for microbiology cultures: 70/80 (88%) LMIC and 40/43 (93%) HIC hospitals (Table 2). An onsite microbiology laboratory was available more frequently in HIC (36/43, 84%) than LMIC (53/80, 66%) hospitals (\( P = 0.03 \)). HIC had no restrictions on testing, whereas some LMIC had to send samples to an off-site laboratory (6/70, 9%) or had restrictions on which patients/samples to test because of capacity and cost (11/70, 16%). For hospitals with microbiology

---

**FIGURE 2.** Access to AMS and IPC programs and personnel. Proportion of LMIC and HIC healthcare settings with (A) a formal AMS program or IPC program; (B) types of AMS and (C) types of IPC personnel.

**FIGURE 3.** Specific AMS resources and interventions: (A) Use of antimicrobial prescribing guidelines in all healthcare settings; (B) Use of point-of-care interventions relating to antimicrobial prescribing in children in hospitals; (C) Reliable antibiotic availability for children in hospitals. Abx, antibiotic; CAI & HAI, guidelines differentiating between community-acquired infections and hospital-acquired infections. *In healthcare settings with hematology/oncology services.
capabilities, blood culture results were notified to the treating clinician within 24 hours of a positive result in 24/40 (60%) and within 48 hours in 39/40 (98%) HIC hospitals. In LMIC hospitals, in contrast, only 15/67 (22%) received notification within 24 hours and 43/67 (64%) within 48 hours (both \( P < 0.001 \)). Patients more frequently self-funded microbiology investigations in LMIC than HIC hospitals (33/70 [47%] versus 1/40 [3%], \( P < 0.001 \)).

More HIC than LMIC hospitals reported having a strategy to address increasing AMR (24/40 [60%] versus 26/70 [37%], \( P = 0.02 \)). Globally, these strategies commonly included strengthening AMS services and IPC activities to reinforce guidelines, education and surveillance.

### Education About Antibiotic Use and Infection Control in Children

Regular or required education on best practice in antimicrobial prescribing occurred in 15/89 (17%) LMIC and 13/46 (28%) HIC healthcare settings (\( P = 0.1 \)). Within LMIC settings, 80% of regular antimicrobial and 73% of IPC education occurred in tertiary pediatric hospitals or large/medium public hospitals. Regular or required education on best practice in infection control was more common in both settings and occurred in 22/89 (25%) LMIC healthcare settings and 21/46 (46%) HIC settings (\( P = 0.01 \)).

Respondents from 24/89 (27%) LMIC settings and 28/46 (61%) HIC settings (\( P = 0.0001 \)) were aware of public health campaigns or messaging around antibiotic use or infection control aimed at the general public in their countries. Globally, these were most commonly World Antibiotic Awareness Week, Anti- biotic Information Day, Ministry of Health campaigns through print, broadcast and social media.

### Barriers to Progress

The two most common perceived barriers to AMS for pediatric patients in both healthcare settings were (1) lack of education about antibiotics and (2) lack of support and enforcement from hospital management. In LMIC, an additional barrier was lack of acknowledgment by senior doctors of the importance of AMS. In HIC, the next most commonly reported barrier was lack of personnel resources to prioritize AMS.

The three most common perceived barriers to infection control for pediatric patients encountered in healthcare settings were identical in both settings: (1) lack of education about infection control, (2) lack of personnel to address this as a priority and (3) lack of support from senior hospital clinicians to change practice. The most significant barrier identified in both LMIC and HIC settings was lack of resources. In LMIC, these resources were personnel/

### Table 2. Access to Microbiology Laboratory Services

|                      | LMIC Hospitals, N (%) | HIC Hospitals, N (%) | \( P \) Value |
|----------------------|-----------------------|----------------------|--------------|
| **Availability of culture types** |                       |                      |              |
| Urine                | 69 (86)               | 40 (93)              | 0.03         |
| Cerebrospinal fluid | 62 (78)               | 40 (93)              | < 0.01       |
| Blood                | 67 (84)               | 40 (93)              | 0.02         |
| **Notification of positive blood culture result** |                       |                      |              |
| Within 24 h          | 15/67 (22)            | 24/40 (60)           | < 0.001      |
| Within 48 h          | 43/67 (64)            | 39/40 (98)           | < 0.001      |
| **Antibiotic susceptibility testing** |                       |                      |              |
| Always/usually       | 59 (74)               | 38 (88)              | < 0.01       |
| Restricted to sample type/patient group | 8 (10)               | 2 (5)                | 0.5          |
| Occasionally/never   | 3 (4)                 | 0 (0)                | 0.6          |
| Cascade reporting    | 38 (48)               | 29 (67)              | < 0.01       |
| Periodic updates of local antibiogram | 36 (45)               | 35 (81)              | < 0.001      |
Despite reducing inappropriate antimicrobial prescribing in these guidelines tended to be less commonly used in LMIC than HIC, different roles. In contrast to the expense of employing subspecialists, this disparity reflects differences in resourcing for personnel and defining outcome measures of effectiveness. Likewise, standard IPC measures designed for adult care are not necessarily transferrable to neonatal and pediatric populations without addressing differences in pathophysiology of healthcare-associated infections (eg, differences in immunity, device utilization, family-centered care environment). The most common AMS personnel were general pediatricians in LMIC and pediatric/adult ID subspecialists in HIC settings. This disparity reflects differences in resourcing for personnel and the consequent need for healthcare staff in LMIC to cover multiple different roles. In contrast to the expense of employing subspecialists, antimicrobial guidelines are relatively inexpensive. However, guidelines tended to be less commonly used in LMIC than HIC, despite reducing inappropriate antimicrobial prescribing in these settings. There was relatively low awareness of the existence of national/international guidelines for antibiotic choice and duration. Other reasons may relate to difficulties in developing local guidelines without robust local susceptibility data, uncertainty in adapting national or WHO guidelines or inadequate dissemination. This needs further exploration.

There was decreased availability of the WHO Access Watch Reserve approach to antibiotics in LMIC than HIC settings. In fact, the reliable availability of WHO Access (essential and widely available) antibiotics was limited to one-third of LMIC healthcare settings, with fewer than half of LMIC settings conducting audits of antibiotic use in children. This highlights the importance of balancing improved access with avoiding excess use, especially for children and neonates. These factors must be addressed, if the WHO target is to be reached redirecting use of access antibiotics to more than 60% of all antimicrobials.

Microbiology services are considered fundamental to AMS with the majority of LMIC hospitals in this survey having access to bacterial culture (although still not all). However, the extent of this access is questionable. Limitations included that 1 in 6 hospitals had restrictions on sample processing due to capacity or cost, delays in clinician notification of results and patients needing to self-fund investigations. Improving the effectiveness of culture results requires not only access to a microbiology laboratory but improvements in systems and resources.

The most common IPC intervention in both LMIC and HIC was promoting hand hygiene, which has a strong evidence-base in reducing healthcare-associated infections and the transmission of resistant pathogens. There is room for improvement, however, as almost 1 in 5 pediatric healthcare settings in LMIC and HIC were not promoting this inexpensive effective strategy. In addition, LMIC hospitals had access to fewer resources such as sinks near patient beds and reliable water supply to support effective hand hygiene. A major difference between LMIC and HIC was the reuse of equipment. Limited resources necessitate pragmatic reuse of essential equipment, but this needs to be supported by reliable systems such as sterilization if spread of infection is to be prevented.

The marked imbalance between LMIC and HIC in pediatric AMS and IPC resources and activities calls for a collaborative international approach to combat AMR, a global public health problem. Because of perceived lower morbidity and mortality from AMR in children, they are being left behind in efforts to improve AMS and IPC effectiveness. However, success stories such as childhood vaccination show the impact of strong leadership and international collaboration. A key priority identified from this survey in all settings, but especially LMIC, is the implementation of systematic, ongoing, management-supported education programs in AMS and IPC. Additionally, given the quantitative and qualitative disparity between LMIC and HIC, an important next step would be a cost-effectiveness analysis of all AMS/IPC interventions to determine the greatest impact for children with limited resources. Concerted efforts, supported by HIC, will be needed to improve advocacy, facilitate inexpensive approaches to reliable antibiotic access and improved sanitation standards for healthcare facilities, in addition to expanding logistical access to microbiology. International organizations can share resources, establish research partnerships, develop specialist training of healthcare professionals and facilitate access to national/international professional networks, to support implementation of context-specific AMS and IPC strategies with global impact.

ACKNOWLEDGMENTS

We would like to thank all participants in this survey, including Dr. A.G. Falade, Dr. A. Hokororo, Dr. A.M. de Sousa da Silva, Dr. A.M. Jibril, Dr. A.K. Singh, Dr. A. Gakuba, Dr. A. Khhatami, Ms. A. Kaul, Dr. A. Khiteva, Dr. A. Bowen, Dr. A. Mishra, Dr. A. Jindal, Dr. A. van der Hoeven, Dr. B. Adeefunke, Dr. D.B. Oluwabasoye, Dr. B. Ogubnosi, Dr. B. Ramachandran, Dr. B. Orwell, Dr. C. Dias, Dr. C. Rongkavitil, Dr. C. Umuozoch, Dr. D. Pavez, Dr. D. Lapatetirisa, Dr. D. Kadynorz, Dr. D. Kuhulanga, Dr. D. Gilbert, Dr. D. Husada, Dr. D. Estrupera, Dr. A.S. Adetunji, Dr. K.D. Yadav, Dr. G.D. Harrison, Dr. M.J. Asghar, Dr. T.J. Mohamed, Dr. H.B. Muhire, Dr. M.Z. Islam, Dr. M. Jassani, Dr. Z. Gatheru, Dr. D.S. Akrasm, Dr. E. Rottunno, Dr. E. Oxytykina, Dr. F. Dicco, Dr. F. Faulan, Dr. F.R. Caimo de Oliveira,
REFERENCES

1. World Health Organization. Global Action Plan on Antimicrobial Resistance. 2015. Available at: https://apps.who.int/iris/bitstream/handle/10665/193736/9789241509763_eng.pdf?sequence=1. Accessed December 14, 2020.

2. Davey P, Marwick CA, Scott CL, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2017;2:CD003543.

3. Donà D, Barbieri E, Daverio M, et al. Implementation and impact of pediatric antimicrobial stewardship programs: a systematic scoping review. Antimicrob Resist Infect Control. 2020;9:3.

4. Ogunsola FT, Mehtar S. Challenges regarding the control of environmental sources of contamination in healthcare settings in low-and middle-income countries - a narrative review. Antimicrob Resist Infect Control. 2020;9:31.

5. Pierce J, Apsanrathananar A, Schellack N, et al. Global antimicrobial stewardship with a focus on low- and middle-income countries. Int J Infect Dis. 2020;96:621–629.

6. Gyssens IC, Werthem HF. Editorial: Antimicrobial Stewardship in Low- and Middle-Income Countries. Front Public Health. 2020;8:617000.

7. Apsanrathananar A, Kwa AL, Chiu CH, et al. Antimicrobial stewardship for acute-care hospitals: an Asian perspective. Infect Control Hosp Epidemiol. 2018;39:1237–1245.

8. Kakkar AK, Shafigq N, Singh G, et al. Antimicrobial stewardship programs in resource constrained environments: understanding and addressing the need of the systems. Front Public Health. 2020;8:140.

9. Bryant PA; Australasian Stewardship of Antimicrobials in Paediatrics group. Antimicrobial stewardship resources and activities for children in tertiary hospitals in Australasia: a comprehensive survey. Med J Aust. 2015;202:134–138.

10. Harris PA, Taylor R, Minor BL, et al; REDCap Consortium. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.

11. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–381.

12. World Bank. World Bank Country and Lending Groups. 2020. Available at: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups. Accessed December 14, 2020.

13. World Health Organization. Antimicrobial stewardship programmes in health-care facilities in low- and middle-income countries: a WHO practical toolkit. Geneva: World Health Organization; 2019.

14. Fay MJ, Bryant PA. Antimicrobial stewardship in children: where to from here? J Paediatr Child Health. 2020;56:1504–1507.

15. Sandora TJ. Hospital epidemiology and infection control for children: report from the society for Healthcare Epidemiology of America Pediatric Leadership Council. J Pediatric Infect Dis Soc. 2014;3:4–6.

16. Balkhy HH, Zingg W. Update on infection control challenges in special pediatric populations. Curr Opin Infect Dis. 2014;27:370–378.

17. Cox JA, Vlieghe E, Mendelson M, et al. Antibiotic stewardship in low- and middle-income countries: the same but different? Clin Microbiol Infect. 2017;23:812–818.

18. Schuts EC, Hulscher MEJL, Mouton JW, et al. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16:847–856.

19. Wilkinson A, Ebata A, MacGregor H. Interventions to reduce antibiotic prescribing in LMICs: a scoping review of evidence from Human and Animal Health Systems. Antibiotics (Basel). 2018;8:82.

20. Bielicki J, Lundin R, Patel S, et al. Antimicrobial stewardship for neonates and children: a global approach. Pediatr Infect Dis J. 2015;34:311–313.

21. Howard P, Pulcini C, Levy Harr G, et al; ESCMID Study Group for Antimicrobial Policies (ESGAP); ISC Group on Antimicrobial Stewardship. An international cross-sectional survey of antimicrobial stewardship programmes in hospitals. J Antimicrob Chemother. 2015;70:1245–1255.

22. Loftus MJ, Guitart C, Tartari E, et al. Hand hygiene in low- and middle-income countries. J Hosp Infect. 2017;202:134–138.

23. Ohi CA, Luther VP. Health care provider education as a tool to enhance antibiotic prescribing practices. Infect Dis Clin North Am. 2014;28:177–193.

24. Monen V, Chubaty A, Clezy K, et al. Infectious diseases and antimicrobial prescribing: online spaced education for junior doctors. J Glob Antimicrob Resist. 2020;22:226–230.

25. Wei X, Zhang Z, Walley JD, et al. Effect of a training and educational intervention for physicians and caregivers on antibiotic prescribing for upper respiratory tract infections in children at primary care facilities in rural China: a cluster-randomised controlled trial. Lancet Glob Health. 2017;5:e1258–e1267.

26. Lynch C, Mahida N, Gray J. Antimicrobial stewardship: a COVID casualty? J Hosp Infect. 2020;106:401–403.